TET inhibitors as potential new cancer drugs - An enzyme that Converts 5-methylcytosine to 5-hydroxymethylcytosine

International Drug Discovery

Volumn 2012, Issue 1, 2012, Pages 21-23

  Chia, Nancy ^a   Wang, Luan ^b   Ruden, Douglas M ^c  

^a Institute of Environmental Health Sciences   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; DIOXYGENASE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TEN ELEVEN TRANSLOCATION PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; DNA METHYLATION; GAIN OF FUNCTION MUTATION; GENE SILENCING; GENOMIC INSTABILITY; GLIOBLASTOMA; GLIOMA; TUMOR SUPPRESSOR GENE; X CHROMOSOME INACTIVATION;

EID: 84863123659     PISSN: 21504792     EISSN: 21504806     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bird, A., Perceptions of epigenetics. Nature, 2007. 447(7143): p. 396-8.
2. Portela, A. and M. Esteller, Epigenetic modifications and human disease. Nature Biotechnology, 2010. 28(10): p. 1057-68.
3. Goll, M.G. and T.H. Bestor, Eukaryotic cytosine methyltransferases. Annu Rev Biochem, 2005. 74: p. 481-514.
4. Penn, N.W., et al., The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. The Biochemical journal, 1972. 126(4): p. 781-90.
5. Kriaucionis, S. and N. Heintz, The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science, 2009. 324(5929): p. 929-30.
6. Tahiliani, M., et al., Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 2009. 324(5929): p. 930-5.
7. Dahl, C., K. Gronbaek, and P. Guldberg, Advances in DNA methylation: 5-hydroxymethylcytosine revisited. Clin Chim Acta, 2011. 412(11-12): p. 831-6.
8. Abdel-Wahab, O., Genetics of the myeloproliferative neoplasms. Current opinion in hematology, 2011. 18(2): p. 117-23.
9. Ndlovu, M.N., H. Denis, and F. Fuks, Exposing the DNA methylome iceberg. Trends in biochemical sciences, 2011.
10. Law, J.A. and S.E. Jacobsen, Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nature reviews. Genetics, 2010. 11(3): p. 204-20.
11. Feng, S., S.E. Jacobsen, and W. Reik, Epigenetic reprogramming in plant and animal development. Science, 2010. 330(6004): p. 622-7.
12. Uribe-Lewis, S., et al., Molecular mechanisms of genomic imprinting and clinical implications for cancer. Expert reviews in molecular medicine, 2011. 13: p. e2.
13. Lim, D.H. and E.R. Maher, Genomic imprinting syndromes and cancer. Advances in Genetics, 2010. 70: p. 145-75.
14. Okano, M., et al., DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell, 1999. 99(3): p. 247-57.
15. Malagnac, F., et al., A gene essential for de novo methylation and development in Ascobolus reveals a novel type of eukaryotic DNA methyltransferase structure. Cell, 1997. 91(2): p. 281-90.
16. Teitell, M. and B. Richardson, DNA methylation in the immune system. Clinical immunology, 2003. 109(1): p. 2-5.
17. Ratan, R.R., Epigenetics and the nervous system: epiphenomenon or missing piece of the neurotherapeutic puzzle? Lancet neurology, 2009. 8(11): p. 975-7.
18. Mehler, M.F., Epigenetics and the nervous system. Annals of Neurology, 2008. 64(6): p. 602-17.
19. Jiang, Y., et al., Epigenetics in the nervous system. The Journal of neuroscience: the official journal of the Society for Neuroscience, 2008. 28(46): p. 11753-9.
20. Costa, F.F., Epigenomics in cancer management. Cancer management and research, 2010. 2: p. 255-65.
21. Esteller, M., Cancer epigenomics: DNA methylomes and histone-modification maps. Nature reviews. Genetics, 2007. 8(4): p. 286-98.
22. Jones, P.A. and S.B. Baylin, The epigenomics of cancer. Cell, 2007. 128(4): p. 683-92.
23. Chen, R.Z., et al., DNA hypomethylation leads to elevated mutation rates. Nature, 1998. 395(6697): p. 89-93.
24. Portela, A. and M. Esteller, Epigenetic modifications and human disease. Nat Biotechnol, 2010. 28(10): p. 1057-68.
25. Chowdhury, R., et al., The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Reports, 2011. 12(5): p. 463-9.
26. Xu, W., et al., Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell, 2011. 19(1): p. 17-30.
27. Baysal, B.E., et al., Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 2000. 287(5454): p. 848-51.
28. Ricketts, C.J., et al., Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Human Mutation, 2010. 31(1): p. 41-51.
29. Tomlinson, I.P., et al., Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genetics, 2002. 30(4): p. 406-10.
30. Cairns, R.A., I.S. Harris, and T.W. Mak, Regulation of cancer cell metabolism. Nature Reviews. Cancer, 2011. 11(2): p. 85-95.
31. Dang, L., et al., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2010. 465(7300): p. 966.
32. Marcucci, G., et al., IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2010. 28(14): p. 2348-55.
33. Ward, P.S., et al., The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 2010. 17(3): p. 225-34.